Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Repligen CorporationNASDAQ: RGEN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $23.77M fell 4.0% year over year, ahead of the -7.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.
Context
- Depreciation & amortization amounted to 13.1% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.0% holds above the trailing-twelve-month pace of -7.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 96.96M USD
- Year-over-year change
- +12.0%
- 4-year CAGR
- +26.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.96M | +12.0% |
| FY2024 | 2024-12-31 | 86.56M | +0.5% |
| FY2023 | 2023-12-31 | 86.11M | +51.0% |
| FY2022 | 2022-12-31 | 57.01M | +48.3% |
| FY2021 | 2021-12-31 | 38.45M | — |
Depreciation & Amortization vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's LTM Jun 2026 depreciation & amortization of $97.31M is the 6th largest of the 9 companies compared; the peer median is $164.86M.
- Its year-over-year change of -7.0% is the 6th highest of 9, against a peer median of -4.2%.
- Depreciation & amortization amounts to 12.4% of revenue for RGEN, versus a peer median of 6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.11B | +11.2% | -6.3% | 6.6% | |
| LTM Jun 2026 | $418.4M | +3.1% | +0.4% | 6.4% | |
| LTM Jul 2026 | $271M | -5.2% | -3.1% | 3.7% | |
| LTM Jun 2026 | $202.13M | +7.0% | -2.4% | 9.6% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Jun 2026 | $97.31M | -7.0% | +19.4% | 12.4% | |
| LTM Sep 2026 | $96.75M | -8.8% | -3.2% | 7.9% | |
| LTM Jun 2026 | $56.96M | -3.2% | +16.6% | 27.3% | |
| LTM Mar 2026 | $4M | -48.5% | -34.2% | 4.0% | |
| Peer median (excluding RGEN) | $164.86M | -4.2% | -2.8% | 6.5% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 128.29M | 185.96M | 41.58M | (25.51M) | 48.89M |
| Depreciation & Amortization | 38.45M | 57.01M | 86.11M | 86.56M | 96.96M |
| Deferred Income Tax | 6.52M | (1.35M) | 2.32M | (16.79M) | (3.37M) |
| Stock-Based Compensation | 27.5M | 27.32M | 25.58M | 48.07M | 32.61M |
| Change in Working Capital | (102.13M) | (69.84M) | (8.64M) | 60.92M | (50.88M) |
| Accounts Receivables | (46.53M) | (3.6M) | (3.31M) | (14.03M) | (17.17M) |
| Inventory | (89.78M) | (57.2M) | 40.97M | 56.9M | (14.95M) |
| Accounts Payables | 19.52M | (8.2M) | (9.8M) | 12.9M | (4.15M) |
| Other Working Capital | 14.66M | (841K) | (36.5M) | 5.16M | (14.62M) |
| Other Non-Cash Items | 20.39M | (27.01M) | (33.03M) | 22.15M | (6.79M) |
| Operating Cash Flow | 119.02M | 172.08M | 113.92M | 175.39M | 117.42M |
| Capital Expenditures | (67.09M) | (133.35M) | (38.99M) | (32.91M) | (23.52M) |
| Acquisitions (Net) | (149.89M) | 0 | (186.64M) | (54.77M) | (70.33M) |
| Purchases of Investments | 0 | (100M) | 0 | 0 | (200.26M) |
| Sales of Investments | 0 | 0 | 102.32M | 0 | 0 |
| Other Investing Activities | (4.19M) | (48.4M) | (2.73M) | (5.94M) | (4.37M) |
| Investing Cash Flow | (221.17M) | (233.24M) | (123.28M) | (86.38M) | (298.47M) |
| Debt Repayment | (21K) | 0 | 290.09M | (69.94M) | 0 |
| Common Stock Issued | 3.88M | 3.71M | 1.08M | 4.29M | 3.18M |
| Common Stock Repurchased | 0 | 0 | (14.39M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.9M) | (17.04M) | (27.82M) | (17.26M) | (18.38M) |
| Financing Cash Flow | 961K | (13.34M) | 248.96M | (82.9M) | (15.21M) |
| Effect of Forex Changes | (12.29M) | (5.87M) | (11.74M) | (77K) | 4.93M |
| Net Change in Cash | (113.48M) | (80.36M) | 227.87M | 6.03M | (191.33M) |
| Free Cash Flow | 51.93M | 38.74M | 74.93M | 142.49M | 93.9M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.